https://www.thebodypro.com/category/adverse-events-comorbidities-hiv/tag/conference-coverage

The Latest

George Ioannou, M.D., M.S.

All Veterans With Hepatitis C Could Be Cured Within 3 Years

The Department of Veterans Affairs (VA) estimates it can cure the remaining 124,000 patients living with hepatitis C in VA care within the next three years, after record treatment and cure numbers in 2015.

Now That We Have a Cure for Hepatitis C, What Are the Next Treatment Challenges? Img

Now That We Have a Cure for Hepatitis C, What Are the Next Treatment Challenges?

Within the next few years, several pipeline hepatitis C drugs are expected to be approved in the U.S., ensuring that even the most difficult-to-treat patients can be cured -- but what challenges remain?

Mei Lu, Ph.D.

Cirrhosis Increases 40% in Individuals Living With Hepatitis C

The prevalence of liver cirrhosis increased by almost 40% from 2006-2014, going from 20.5% to 28.8%Ed among individuals living with hepatitis C in the U.S.

Stefan Zeuzem, M.D.

Fixed-Dose Sofosbuvir/Velpatasvir/Voxilaprevir Cures 97% of Treatment-Experienced Hepatitis C Patients

Only 6% of 9500 people living with hepatitis C in a U.S. clinic cohort started direct-acting antivirals (DAAs) in 2014 and 2015, according to a recent study.

Low Uptake of Direct-Acting Antivirals for Hepatitis C in U.S. Clinics -- Race and Income Key Factors Img

Low Uptake of Direct-Acting Antivirals for Hepatitis C in U.S. Clinics -- Race and Income Key Factors

Only 6% of 9500 people living with hepatitis C in a U.S. clinic cohort started direct-acting antivirals (DAAs) in 2014 and 2015, according to a recent study.

High Hepatitis C Cure Rates With Harvoni and Viekira Pak in Veterans With Genotype 1 Img

High Hepatitis C Cure Rates With Harvoni and Viekira Pak in Veterans With Genotype 1

Hepatitis C regimens containing ledipasvir/sofosbuvir (Harvoni) or paritaprevir/ritonavir/ombitasvir and dasabuvir (Viekira Pak) cured almost 17,500 patients in the Veterans Affairs (VA) health care system.

Curing Hepatitis C Lowers but Does Not Eliminate Risk of Liver Cancer Img

Curing Hepatitis C Lowers but Does Not Eliminate Risk of Liver Cancer

Achieving hepatitis C (HCV) cure with an interferon-based regimen lowered risk of hepatocellular carcinoma (HCC) by 80% in a large Canadian cohort, but cases of HCC still arose after HCV cure.

Treatment With ABT-493/ABT-530 Cures 99% of Patients With Hepatitis C Genotype 2 Img

Treatment With ABT-493/ABT-530 Cures 99% of Patients With Hepatitis C Genotype 2

Almost everyone taking immediate ABT-493/ABT-530 (glecaprevir/pibrentasvir, G/P) in an international placebo-controlled study were cured of hepatitis C, without any serious adverse effects.

Eric Lawitz, M.D.

MK3, a One-Pill Triple Direct-Acting Antiviral, Effective for Hepatitis C Genotypes 1, 2, and 3

MK3, a fixed-dose combination of three direct-acting antivirals (DAAs) with different mechanisms of action, provided cure rates exceeding 95% in patients with hepatitis C genotypes 1, 2, or 3.

Fabienne Laraque, M.D., M.P.H.

Coordinated Care in Poor Neighborhoods Overcomes Some Barriers to Hepatitis C Treatment

A comprehensive, coordinated care program implemented by the New York City Department of Health appeared to reduce barriers to HCV therapy, such as mental health conditions, alcohol or drug use, and HIV infection.